- Home
- COLL vs CII Comparison
COLL vs CII Comparison
Compare COLL & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | CII |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | COLL | CII |
|---|---|---|
| Price | $37.35 | $25.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $51.40 | N/A |
| AVG Volume (30 Days) | ★ 433.5K | 62.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $8.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $91.13 | ★ N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $29.19 | $20.43 |
| 52 Week High | $50.79 | $26.17 |
Technical Indicators
Market Signals| Indicator | COLL | CII |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 50.36 |
| Support Level | $33.80 | $24.76 |
| Resistance Level | $38.50 | $26.14 |
| Average True Range (ATR) | 1.42 | 0.44 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 75.38 | 36.43 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About CII Blackrock Capital and Income Fund Inc.
Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing in a portfolio of equity securities of U.S. and foreign issuers. It may invest directly in such securities or synthetically through the use of derivatives. It also seeks to achieve its investment objective by employing a writing (selling) call and put options.